Gastrointestinal stromal tumours (GIST): experience in two hospitals of Bogotá D.C., Colombia (ONCOLGroup study)

Vargas, Carlos Alberto; Cardona, Andrés Felipe; Carranza, Hernán; Otero, Jorge Miguel; Reveiz, Ludovic; Ospina, Édgar; Ojeda, Kelman; Castro, Carlos

Services on Demand

Journal

Article

Indicators

Cited by SciELO
Access statistics

Revista colombiana de Gastroenterología

Print version ISSN 0120-9957On-line version ISSN 2500-7440

Abstract

VARGAS, Carlos Alberto et al. Gastrointestinal stromal tumours (GIST): experience in two hospitals of Bogotá D.C., Colombia (ONCOLGroup study). Rev Col Gastroenterol [online]. 2008, vol.23, n.3, pp.213-223. ISSN 0120-9957.

Introduction: Gastrointestinal stromal tumours (GIST) are the most frequently occurring mesenchymal neoplasia of the digestive tract and account for around 5% of the sarcomas. Objective: To describe the demographic characteristics and clinical course of 31 patients suffering from GIST who were treated at two hospitals in Bogotá D.C. Materials and methods: The clinical charts of the patients diagnosed as having GIST (immunohistochemistry with CD117+) were reviewed. Results: Patients average age was 58 years; 52% were female and 94% had a functional stage according to Karnofskys performance scale index ≥70%. 55% presented potentially resectable limited disease at the time of diagnosis and the remaining patients had metastasis. The stomach was the main localization of primary tumours (45%), followed by the small intestine (32,3%). Average tumour size was 6,6 and 52% presenting lesions having a fusiform cell pattern. Initial treatment consisted of surgery for 25 of the patients (81%); 19 patients were treated with imatinib 400 mg/day and the complete populations overall survival (OS) rate was 46 months (range, 4,2 to 54,2 months). Those patients with GIST receiving 400 mg/day imatinib achieved a 50% overall response, 88% clinical benefit and 22 months progression free survival for the group of responders. For patients which began with limited disease this time were 49 months and 31 for those having metastatic disease. Conclusions: These results agreed with prolonged OS, especially for the group of subjects who began with limited disease and for those who classified at very low and low risk groups.

Keywords : Gastrointestinal tract; mesenchymal cells; gastrointestinal stromal tumour; gastrointestinal stromal neoplasia; imatinib; tyrosine-kinase; c-kit.

· abstract in Spanish · text in Spanish · Spanish (

pdf )